Document is current

Article History

Received: 10 March 2019

Accepted: 28 June 2019

First Online: 8 July 2019

Ethics approval and consent to participate

: This study was approved by the Institutional Review Boards at the University of Washington and Johns Hopkins University.

: Written informed consent was obtained from the patient whose radiographic images are included in this manuscript. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: JL: none.MDS: none.SR: none.OA: none.WHS: Consultant for Bristol-Myers Squibb, Merck, Novartis, Regeneron. Research Funding from Bristol-Myers Squibb, Merck, Novartis.AWS: Consultant for Merck and Bristol-Myers Squibb. Research funding from Biohaven, Bristol-Myers Squibb, Merck, Prometheus, and Viralytics.SB: advisory board participation (with honorarium) from Genentech, EMD-Serono, Sanofi-Genzyme and Bristol-Myers-Squibb (BMS) and research funding to his institution (University of Washington) from Oncosec Medical Inc., EMD-Serono, Merck, BMS, NantKwest and Immune Design.EJL: Consultant for Array BioPharma, Bristol-Myers Squibb, Castle Biosciences, EMD Serono, Macrogenics, Merck, Millennium, Novartis. Research Funding from Bristol-Myers Squibb, Merck, Sysmex. Patent application pending: Method of preventing organ transplant rejections using agonists to the PD-1 checkpoint pathway.